Mene Pangalos, the AstraZeneca executive, said the U.S. trial is more of a confirmatory trial, according to a client note. The trial will not have much bearing to the vaccine candidate’s global approval chances since that will be determined by the other trials currently in the UK, Brazil, South Africa, Japan and India, the Guggenheim note said.
